In the study by Yan et al. (2025), the focus is on a novel targeted therapy for relapsed/refractory multiple myeloma, which is a challenging stage of the disease to treat. The therapy targets G protein-coupled receptor, class C Group 5 member D (GPRC5D), a molecule found on the surface of myeloma cells. The rationale behind this approach is that as patients with relapsed myeloma often become resistant to existing treatments, introducing a new target like GPRC5D could be an effective strategy.
The review by Yan et al. systematically summarizes the advancements in GPRC5D-targeted therapies, indicating that this could be a promising avenue for future treatment options. While the article does not provide specific data on clinical outcomes, it emphasizes the importance of exploring new targets to improve the prognosis for patients with relapsed/refractory multiple myeloma. The ongoing studies mentioned in the review are expected to provide valuable insights and a foundation for the development of these therapies.
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
More Info 
Add to Calendar 